IL290889A - Pyrrolopyrimidine compounds inhibit perk - Google Patents

Pyrrolopyrimidine compounds inhibit perk

Info

Publication number
IL290889A
IL290889A IL290889A IL29088922A IL290889A IL 290889 A IL290889 A IL 290889A IL 290889 A IL290889 A IL 290889A IL 29088922 A IL29088922 A IL 29088922A IL 290889 A IL290889 A IL 290889A
Authority
IL
Israel
Prior art keywords
pyrrolopyrimidine compounds
perk inhibiting
perk
inhibiting
pyrrolopyrimidine
Prior art date
Application number
IL290889A
Other languages
English (en)
Hebrew (he)
Original Assignee
Hibercell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hibercell Inc filed Critical Hibercell Inc
Publication of IL290889A publication Critical patent/IL290889A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL290889A 2019-08-29 2022-02-24 Pyrrolopyrimidine compounds inhibit perk IL290889A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962893528P 2019-08-29 2019-08-29
PCT/US2020/048621 WO2021041975A1 (en) 2019-08-29 2020-08-28 Perk inhibiting pyrrolopyrimidine compounds

Publications (1)

Publication Number Publication Date
IL290889A true IL290889A (en) 2022-04-01

Family

ID=72470610

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290889A IL290889A (en) 2019-08-29 2022-02-24 Pyrrolopyrimidine compounds inhibit perk

Country Status (12)

Country Link
US (1) US20220356186A1 (cg-RX-API-DMAC7.html)
EP (1) EP4021908A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022546414A (cg-RX-API-DMAC7.html)
KR (1) KR20220066290A (cg-RX-API-DMAC7.html)
CN (1) CN114710956A (cg-RX-API-DMAC7.html)
AU (1) AU2020336975A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022003584A2 (cg-RX-API-DMAC7.html)
CA (1) CA3152508A1 (cg-RX-API-DMAC7.html)
IL (1) IL290889A (cg-RX-API-DMAC7.html)
MX (1) MX2022002446A (cg-RX-API-DMAC7.html)
PH (1) PH12022550491A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021041975A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041973A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting compounds
CA3182276A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
CN117597346A (zh) * 2021-04-05 2024-02-23 哈利亚治疗公司 Nek7抑制剂
JP2024513227A (ja) * 2021-04-05 2024-03-22 ハリア・セラピューティクス・インコーポレイテッド Nek7阻害剤
US20240287081A1 (en) * 2021-06-09 2024-08-29 Icahn School Of Medicine At Mount Sinai Perfluoroalkane substituted pyrazolo[3,4-d]pyrimidin and pyrrolo[2,3-d]pyrimidin compounds and uses thereof
US20250000859A1 (en) 2021-08-25 2025-01-02 Alesta Therapeutics BV Use of gcn2 inhibitors in treating cancer
GB202407386D0 (en) 2024-05-24 2024-07-10 Apollo Ap45 Ltd 1H-pyrazolo(4,3-D)pyrimidine derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903297A (en) 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
BR9808281A (pt) * 1997-03-19 2000-05-16 Basf Ag Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto
US7863444B2 (en) * 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
EP3067356B1 (en) * 2013-11-08 2018-07-04 ONO Pharmaceutical Co., Ltd. Pyrrolo pyrimidine derivative
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
WO2016085160A2 (ko) * 2014-11-28 2016-06-02 (주)네오팜 발모촉진용 또는 탈모방지용 조성물
GB201508747D0 (en) * 2015-05-21 2015-07-01 Univ Edinburgh Compounds
WO2017046739A1 (en) * 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Imidazolidinone derivatives as inhibitors of perk
TW201722957A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產(第二)有限公司 化學化合物
EP3481831B1 (en) * 2016-07-07 2023-09-06 Daewoong Pharmaceutical Co., Ltd. 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same
SI3612519T1 (sl) * 2017-04-18 2022-04-29 Eli Lilly And Company Fenil-2-hidroksi-acetilamino-2-metil-fenilne spojine

Also Published As

Publication number Publication date
KR20220066290A (ko) 2022-05-24
BR112022003584A2 (pt) 2022-05-24
CA3152508A1 (en) 2021-03-04
JP2022546414A (ja) 2022-11-04
WO2021041975A1 (en) 2021-03-04
AU2020336975A1 (en) 2022-03-31
PH12022550491A1 (en) 2023-02-06
CN114710956A (zh) 2022-07-05
US20220356186A1 (en) 2022-11-10
EP4021908A1 (en) 2022-07-06
MX2022002446A (es) 2022-06-02

Similar Documents

Publication Publication Date Title
IL289463A (en) Agonist-gipr compounds
SG11202100525SA (en) Pyrrolopyrimidine itk inhibitors
GB202018573D0 (en) No details
IL277071A (en) Aminopyrizine diol compounds as PI3K-y inhibitors
GB201905721D0 (en) Compounds
GB201914860D0 (en) Inhibitor compounds
IL290087A (en) inhibitory substances
GB201910305D0 (en) Compounds
IL279698A (en) Compounds that increase proteasome activity
GB201916915D0 (en) Compounds
GB201908536D0 (en) Compounds
GB201905328D0 (en) Inhibitor compounds
GB201910304D0 (en) Compounds
GB201908171D0 (en) Compounds
GB201908095D0 (en) Carboxy-MIDA-boronate compounds
HK40077027A (en) Perk inhibiting pyrrolopyrimidine compounds
HK40077026A (en) Perk inhibiting compounds
HK40055501A (en) Pyrrolopyrimidine itk inhibitors
GB201919205D0 (en) Compounds
GB201918761D0 (en) Compounds
GB201918424D0 (en) Compounds
GB201917895D0 (en) Compounds
GB201917893D0 (en) Compounds
GB201917891D0 (en) Compounds
GB201916847D0 (en) Compounds